multiple dose bio­equi­va­lence study [Design Issues]

posted by wienui  – Germany/Oman, 2020-08-10 10:00 (841 d 22:45 ago) – Posting: # 21847
Views: 1,695

Hi Loky do & Helmut,

❝ If we have solifenacin 6 mg (immediate-release) / tamsulosin 0.4 mg modified-release product combination, is multiple-dose bioequivalence study required to be submitted to the European authorities in addition to fast & fed studies, as there is no specific guidance for this product & in GCC region fast & fed studies only accepted.


Yes, you need an MD (SS) study as Helmut mentioned above. Please note that the GCC GL was adopted originally from the EMA GL, therefore it follows it, although some points could be not clear included.

Cheers,
Osama

Complete thread:

UA Flag
Activity
 Admin contact
22,418 posts in 4,693 threads, 1,598 registered users;
17 visitors (0 registered, 17 guests [including 6 identified bots]).
Forum time: 07:45 CET (Europe/Vienna)

Intellect distinguishes between the possible and the impossible;
reason distinguishes between the sensible and the senseless.
Even the possible can be senseless.    Max Born

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5